Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

David R. Parkinson, Richard I. Fisher, Anthony A. Rayner, Elisabeth M. Paietta, Kim A. Margolin, Geoffrey R. Weiss, James W. Mier, Mario Sznol, Ellen R. Gaynor, Michael H. Bar, Rasim A. Gucalp, David H. Boldt, Bonnie Mills, Michael J. Hawkins

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Forty-seven patients with metastatic or unresectable renal cell carcinoma were treated with interleukin-2 (IL-2) and lymphokine-activated killer (LAK)-cell therapy, using a hybrid IL-2 regimen. IL-2 was administered initially by intravenous bolus (105 U/kg [Cetus Corp, Emeryville, CA] every 8 hours for 3 days) during the priming phase, and subsequently by continuous infusion (3 × 106 U/m2 for 6 days); during this second treatment period, in vitro-generated LAK cells were administered. Despite selection of patients for good performance status (PS) (29, PS 0; 18, PS 1) prior nephrectomy (43 of the 47 patients), and low tumor burden, the response rate was low (two complete [CRs] and two partial responses [PRs], for an overall objective response rate of 9%). Toxicity was comparable to that experienced with the high-dose bolus regimen. These results suggest that the dose and schedule of IL-2 administration may influence the likelihood of response to IL-2 in renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)1630-1636
Number of pages7
JournalJournal of Clinical Oncology
Volume8
Issue number10
StatePublished - Oct 1990
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Renal Cell Carcinoma
Interleukin-2
Therapeutics
Cell- and Tissue-Based Therapy
Tumor Burden
Nephrectomy
Patient Selection
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells : Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. / Parkinson, David R.; Fisher, Richard I.; Rayner, Anthony A.; Paietta, Elisabeth M.; Margolin, Kim A.; Weiss, Geoffrey R.; Mier, James W.; Sznol, Mario; Gaynor, Ellen R.; Bar, Michael H.; Gucalp, Rasim A.; Boldt, David H.; Mills, Bonnie; Hawkins, Michael J.

In: Journal of Clinical Oncology, Vol. 8, No. 10, 10.1990, p. 1630-1636.

Research output: Contribution to journalArticle

Parkinson, DR, Fisher, RI, Rayner, AA, Paietta, EM, Margolin, KA, Weiss, GR, Mier, JW, Sznol, M, Gaynor, ER, Bar, MH, Gucalp, RA, Boldt, DH, Mills, B & Hawkins, MJ 1990, 'Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen', Journal of Clinical Oncology, vol. 8, no. 10, pp. 1630-1636.
Parkinson, David R. ; Fisher, Richard I. ; Rayner, Anthony A. ; Paietta, Elisabeth M. ; Margolin, Kim A. ; Weiss, Geoffrey R. ; Mier, James W. ; Sznol, Mario ; Gaynor, Ellen R. ; Bar, Michael H. ; Gucalp, Rasim A. ; Boldt, David H. ; Mills, Bonnie ; Hawkins, Michael J. / Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells : Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 10. pp. 1630-1636.
@article{524606a9957e42299f829f15df69bf16,
title = "Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen",
abstract = "Forty-seven patients with metastatic or unresectable renal cell carcinoma were treated with interleukin-2 (IL-2) and lymphokine-activated killer (LAK)-cell therapy, using a hybrid IL-2 regimen. IL-2 was administered initially by intravenous bolus (105 U/kg [Cetus Corp, Emeryville, CA] every 8 hours for 3 days) during the priming phase, and subsequently by continuous infusion (3 × 106 U/m2 for 6 days); during this second treatment period, in vitro-generated LAK cells were administered. Despite selection of patients for good performance status (PS) (29, PS 0; 18, PS 1) prior nephrectomy (43 of the 47 patients), and low tumor burden, the response rate was low (two complete [CRs] and two partial responses [PRs], for an overall objective response rate of 9{\%}). Toxicity was comparable to that experienced with the high-dose bolus regimen. These results suggest that the dose and schedule of IL-2 administration may influence the likelihood of response to IL-2 in renal cell carcinoma.",
author = "Parkinson, {David R.} and Fisher, {Richard I.} and Rayner, {Anthony A.} and Paietta, {Elisabeth M.} and Margolin, {Kim A.} and Weiss, {Geoffrey R.} and Mier, {James W.} and Mario Sznol and Gaynor, {Ellen R.} and Bar, {Michael H.} and Gucalp, {Rasim A.} and Boldt, {David H.} and Bonnie Mills and Hawkins, {Michael J.}",
year = "1990",
month = "10",
language = "English (US)",
volume = "8",
pages = "1630--1636",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells

T2 - Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

AU - Parkinson, David R.

AU - Fisher, Richard I.

AU - Rayner, Anthony A.

AU - Paietta, Elisabeth M.

AU - Margolin, Kim A.

AU - Weiss, Geoffrey R.

AU - Mier, James W.

AU - Sznol, Mario

AU - Gaynor, Ellen R.

AU - Bar, Michael H.

AU - Gucalp, Rasim A.

AU - Boldt, David H.

AU - Mills, Bonnie

AU - Hawkins, Michael J.

PY - 1990/10

Y1 - 1990/10

N2 - Forty-seven patients with metastatic or unresectable renal cell carcinoma were treated with interleukin-2 (IL-2) and lymphokine-activated killer (LAK)-cell therapy, using a hybrid IL-2 regimen. IL-2 was administered initially by intravenous bolus (105 U/kg [Cetus Corp, Emeryville, CA] every 8 hours for 3 days) during the priming phase, and subsequently by continuous infusion (3 × 106 U/m2 for 6 days); during this second treatment period, in vitro-generated LAK cells were administered. Despite selection of patients for good performance status (PS) (29, PS 0; 18, PS 1) prior nephrectomy (43 of the 47 patients), and low tumor burden, the response rate was low (two complete [CRs] and two partial responses [PRs], for an overall objective response rate of 9%). Toxicity was comparable to that experienced with the high-dose bolus regimen. These results suggest that the dose and schedule of IL-2 administration may influence the likelihood of response to IL-2 in renal cell carcinoma.

AB - Forty-seven patients with metastatic or unresectable renal cell carcinoma were treated with interleukin-2 (IL-2) and lymphokine-activated killer (LAK)-cell therapy, using a hybrid IL-2 regimen. IL-2 was administered initially by intravenous bolus (105 U/kg [Cetus Corp, Emeryville, CA] every 8 hours for 3 days) during the priming phase, and subsequently by continuous infusion (3 × 106 U/m2 for 6 days); during this second treatment period, in vitro-generated LAK cells were administered. Despite selection of patients for good performance status (PS) (29, PS 0; 18, PS 1) prior nephrectomy (43 of the 47 patients), and low tumor burden, the response rate was low (two complete [CRs] and two partial responses [PRs], for an overall objective response rate of 9%). Toxicity was comparable to that experienced with the high-dose bolus regimen. These results suggest that the dose and schedule of IL-2 administration may influence the likelihood of response to IL-2 in renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0025083445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025083445&partnerID=8YFLogxK

M3 - Article

C2 - 2213100

AN - SCOPUS:0025083445

VL - 8

SP - 1630

EP - 1636

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -